Graham R. Foster, Kosh Agarwal, Matthew E. Cramp, Sulleman Moreea, Stephen Barclay, Jane Collier, Ashley S. Brown, Stephen D. Ryder, Andrew Ustianowski, Daniel M. Forton, Ray Fox, Fiona Gordon, William M. Rosenberg, David J. Mutimer, Jiejun Du, Christopher L. Gilbert, Ernest Asante‐Appiah, Janice Wahl, Michael N. Robertson, Eliav Barr, Barbara Haber – 23 February 2018 – Many direct‐acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis.